The trajectory of copyright's flagship drug presents a nuanced case for stakeholders in the pharmaceutical sector. While initially a phenomenal success, generating billions, the patent lapse and the subsequent flood of off-brand versions have drastically impacted earnings. This poses questions about the future sustainability of similar therapeut… Read More